The results described in this manuscript suggest that regardless of the p53 status of AML cells and the mechanisms of response, DNA-PK inhibition effectively sensitizes AML cells to Mylotarg in vitro and in vivo. Here, PRKDC is linked to acute myeloid leukemia.